Education:

Concordia University: Natural Science (Biology/Math), B.A.

About:

Stephanie Mull currently serves as the Director of Project Management at Proxima Clinical Research, Inc. Proxima is a contract research organization focused on assisting emerging pharmaceutical and medical device companies in clinical product development.

Stephanie has over 20 years of clinical research experience working from the site, CRO, and sponsor perspectives. Prior to joining the Proxima team, Stephanie was Sr. Project Manager at the CRO MedSource, the Strategic Alliance Manager at McKesson/US Oncology, and the GU/GYN Program Manager at US Oncology. While at MedSource, Stephanie successfully led a global team to completion of a phase III trial for subjects with super refractory status epilepticus, and served in a consultancy role for a CNS biopharmaceutical company, supporting the management of a suite of MDD trials. During her time at US Oncology she developed, secured, and managed strategic partnerships with multiple large pharmaceutical companies and led the GU/GYN operations program, overseeing and directing a team of project and data managers. She has also held roles managing multiple oncology, cardiology and allergy & asthma trials. Stephanie received a Natural Science (biology/math) degree from Concordia University in St. Paul, MN.

Positions and Honors:

Proxima Clinical Research, Inc., Houston, Texas
Director of Project Management

MedSource, Raleigh, NC
Sr. Project Manager

US Oncology, Inc./McKesson Specialty Health, Woodlands, Texas
Sr. Manager, Strategic Accounts and Alliances

Manager, Alliances and Operations

Manager, Research Programs – GU/GYN

Sr. Project Manager

Project Manager

Allergy and Asthma Associates, Houston, Texas
Clinical Research Coordinator

Dallas VA Medical Center – Cardiology Department, Dallas, TX
Clinical Research Coordinator

Research Assistant

University of Iowa – Pharmacology Department, Iowa City, IA
Research Assistant

Contributions to Science:

Ms. Mull has played an important role in the development of the following medical products:

  1. Software as Medical Device for Depression
  2. Medical device for refractory epilepsy
  3. In vitro diagnostic device for detection of SARS-CoV-2 (COVID-19)
  4. Drug for neuroprotection during thrombectomy in stroke
  5. Medical device for treatment of intracranial bifurcation aneurysms
  6. Medical device for liver transplant
  7. Medical device for prostate cancer ablation
  8. In vitro diagnostic device for detection of SARS-CoV-2 (COVID-19)
  9. Medical device (noninvasive transcutaneous spinal cord stimulation) to enhance upper extremity function
  10. Medical device for imaging and analysis of tissue during breast cancer surgery
  11. Drug product for tardive dyskinesia  
  12. Medical Device for hemodynamic measurements of cardiac output and pressures
  13. Medical Device for detection and monitoring of bleeds during endovascular procedures
  14. Drug for Major Depressive Disorder
  15. Drug for Major Depressive Disorder/Insomnia
  16. Drug for Super Refractory Status Epilepticus
  17. Drug for Essential Tremor
  18. Drug for Postpartum Depression
  19. Numerous Drug studies for prostate cancer, kidney cancer, ovarian cancer, breast cancer, lung cancer, bladder cancer, gastrointestinal cancer, brain cancer
  20. Drug for Asthma
  21. Drug for Allergic Rhinitis
  22. Drug for Allergic Rhinitis
  23. Drug for Atrial Fibrillation
  24. Drug for Congestive Heart Failure
Additional Information:
OriginallY From:
Minnesota
Fun Fact:
Stephanie joined her local CrossFit gym 4 ½ years ago and you can find her there 4-5 times a week.
Recent Updates
Knowledge Base Contributions
Frequently Asked Questions
Glossary Terms